How different versions of the ApoE gene affect heart disease and inflammation
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosis
This study is looking at how different versions of a gene called ApoE might affect heart health by influencing fat processing and inflammation in certain cells, which could help find new ways to prevent heart disease for people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10991003 on NIH RePORTER |
What this research studies
This research investigates the role of different genetic variants of the ApoE gene in the development of atherosclerosis, a major cardiovascular disease. By examining how these variants function in various cell types, particularly myeloid cells and adipocytes, the study aims to understand their impact on lipid metabolism and inflammation. The researchers will analyze how ApoE2 and ApoE4 variants influence inflammatory responses and metabolic dysfunctions, potentially leading to accelerated atherosclerosis. This work could uncover new therapeutic strategies to mitigate the risks associated with cardiovascular diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with genetic variations in the ApoE gene, particularly those with ApoE2 or ApoE4 alleles.
Not a fit: Patients without any genetic variations in the ApoE gene or those with unrelated cardiovascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that better manage or prevent cardiovascular diseases linked to genetic factors.
How similar studies have performed: Previous research has shown that understanding genetic factors like ApoE can significantly impact treatment approaches for cardiovascular diseases, indicating a promising avenue for this study.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Hui, David Yiu-Kwan — University of Cincinnati
- Study coordinator: Hui, David Yiu-Kwan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.